Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |